At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Anthony Mato interviewed Dr. Jennifer Woyach. They discussed updated results from the Alliance A041202 trial, which now has longer-term follow-up data.
At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the 2-year results of the Captivate Study evaluating outcomes in previously untreated CLL patients
Acalabrutinib (A) and ibrutinib (I) are both highly effective Bruton tyrosine kinase (BTK) inhibitors approved for the treatment of chronic lymphocytic leukemia (CLL) and given as continuous treatments until disease progression or unacceptable toxicity.
There have been many advances in chronic lymphocytic leukemia small lymphocytic lymphoma (CLL/SLL) treatments over the past decade, with several potent novel agents targeting molecular pathways within CLL cells receiving FDA approval.
Ibrutinib and Venetoclax have as we like to say at the CLL Society orthogonal or complementary mechanisms of action. Ibrutinib inhibits chronic lymphocytic leukemia or CLL cells’ proliferation and gets the cancer cells out of their protective niches in the nodes and bone marrow and into the blood stream
At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Thomas Kipps, Professor of Medicine at the UC San Diego Moores Cancer Center. They discussed the role of targeted therapies such as ibrutinib for the treatment of CLL with high-risk
In this video, Dr. John N. Allan, M.D., an Assistant Professor of Medicine at Weill Cornell Medicine and a CLL specialist at New York-Presbyterian/Columbia University Irving Medical Center, is interviewed by CLL Society founder and Chief Medical Officer, Dr. Brian Koffman, M.D., a retired family physician and a CLL